Log In
BCIQ
Print this Print this
 

INP-104

  Manage Alerts
Collapse Summary General Information
Company Impel NeuroPharma Inc.
DescriptionIntranasal dihydroergotamine (DHE) mesylate
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationMigraine
Indication DetailsTreat drug-resistant migraine in patients who have failed front-line triptan therapy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today